Baxter buys Baxa for $380M; FDA says no to migraine patch;

> Baxter International ($BAX) has agreed to pay $380 million for Baxa, which develops pharmacy technology for oral and IV dose preparation and delivery. The deal is designed to enhance Baxter's nutrition and drug-delivery business. Item | Release

> FDA says no to NuPathe's Zelrix migraine patch. Article

> Drug-eluting balloons in long infrapopliteal arteries could be safe and effective, but more clinical trials are necessary to prove their worth. Story

> Drug delivery patent application of the week: Modified polysaccarides for drug and contrast agent delivery. Patent application